Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(5):918–923. doi: 10.1038/sj.bjc.6690787

Oral contraceptive use and risk of melanoma in premenopausal women

D Feskanich 1, D J Hunter 1,2,3, W C Willett 1,2,4, D Spiegelman 2,5, M J Stampfer 1,2, G A Colditz 1,2,3
PMCID: PMC2374297  PMID: 10555769

Abstract

Melanoma has been increasing in white populations. Incidence rates rise steeply in women until about age 50, suggesting oestrogen as a possible risk factor. Oestrogens can increase melanocyte count and melanin content and cause hyperpigmentation of the skin. We examined prospectively the association between oral contraceptive (OC) use and diagnoses of superficial spreading and nodular melanoma among 183 693 premenopausal white women in the Nurses’ Health Study (NHS) and the Nurses’ Health Study II (NHS II) cohorts. One hundred and forty six cases were confirmed in NHS during follow-up from 1976 to 1994, and 106 cases were confirmed in NHS II from 1989 to 1995. Skin reaction to sun exposure, sunburn history, mole counts, hair colour, family history of melanoma, parity, height and body mass index were also assessed and included in logistic regression models. A significant twofold increase in risk of melanoma (relative risk (RR) = 2.0, 95% confidence interval (CI) 1.2–3.4) was observed among current OC users compared to never users. Risk was further increased among current users with 10 or more years of use (RR = 3.4, 95% CI 1.7–7.0). Risk did not appear elevated among past OC users, even among those with longer durations of use, and risk did not decline linearly with time since last use. In conclusion, risk of premenopausal melanoma may be increased among women who are current OC users, particularly among those with longer durations of use. Further research is needed to determine whether low-dose oestrogen pills in particular are associated with an increase in risk and to describe possible interactions between OC use and sun exposure or other risk factors for melanoma. © 1999 Cancer Research Campaign

Keywords: melanoma, oral contraceptives, oestrogen, premenopausal

Full Text

The Full Text of this article is available as a PDF (67.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bain C., Hennekens C. H., Speizer F. E., Rosner B., Willett W., Belanger C. Oral contraceptive use and malignant melanoma. J Natl Cancer Inst. 1982 Apr;68(4):537–539. [PubMed] [Google Scholar]
  2. Beral V., Evans S., Shaw H., Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer. 1984 Nov;50(5):681–685. doi: 10.1038/bjc.1984.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beral V., Ramcharan S., Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977 Dec;36(6):804–809. doi: 10.1038/bjc.1977.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chaudhuri P. K., Walker M. J., Briele H. A., Beattie C. W., Gupta T. K. Incidence of estrogen receptor in benign nevi and human malignant melanoma. JAMA. 1980 Aug 22;244(8):791–793. [PubMed] [Google Scholar]
  5. Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992 Aug 20;327(8):516–523. doi: 10.1056/NEJM199208203270803. [DOI] [PubMed] [Google Scholar]
  6. Colditz G. A., Manson J. E., Hankinson S. E. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health. 1997 Feb;6(1):49–62. doi: 10.1089/jwh.1997.6.49. [DOI] [PubMed] [Google Scholar]
  7. D'Agostino R. B., Lee M. L., Belanger A. J., Cupples L. A., Anderson K., Kannel W. B. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990 Dec;9(12):1501–1515. doi: 10.1002/sim.4780091214. [DOI] [PubMed] [Google Scholar]
  8. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  9. Fisher R. I., Neifeld J. P., Lippman M. E. Oestrogen receptors in human malignant melanoma. Lancet. 1976 Aug 14;2(7981):337–339. doi: 10.1016/s0140-6736(76)92592-7. [DOI] [PubMed] [Google Scholar]
  10. Gallagher R. P., Elwood J. M., Hill G. B., Coldman A. J., Threlfall W. J., Spinelli J. J. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. Br J Cancer. 1985 Dec;52(6):901–907. doi: 10.1038/bjc.1985.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hannaford P. C., Villard-Mackintosh L., Vessey M. P., Kay C. R. Oral contraceptives and malignant melanoma. Br J Cancer. 1991 Mar;63(3):430–433. doi: 10.1038/bjc.1991.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Helmrich S. P., Rosenberg L., Kaufman D. W., Miller D. R., Schottenfeld D., Stolley P. D., Shapiro S. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J Natl Cancer Inst. 1984 Mar;72(3):617–620. [PubMed] [Google Scholar]
  13. Holly E. A., Cress R. D., Ahn D. K. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol. 1995 May 15;141(10):943–950. doi: 10.1093/oxfordjournals.aje.a117361. [DOI] [PubMed] [Google Scholar]
  14. Holly E. A., Weiss N. S., Liff J. M. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst. 1983 May;70(5):827–831. [PubMed] [Google Scholar]
  15. Holman C. D., Armstrong B. K., Heenan P. J. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer. 1984 Nov;50(5):673–680. doi: 10.1038/bjc.1984.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Holman C. D., Armstrong B. K., Heenan P. J. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst. 1986 Mar;76(3):403–414. [PubMed] [Google Scholar]
  17. Hunter D. J., Manson J. E., Colditz G. A., Chasan-Taber L., Troy L., Stampfer M. J., Speizer F. E., Willett W. C. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception. 1997 Dec;56(6):373–378. doi: 10.1016/s0010-7824(97)00172-8. [DOI] [PubMed] [Google Scholar]
  18. Jelinek J. E. Cutaneous side effects of oral contraceptives. Arch Dermatol. 1970 Feb;101(2):181–186. [PubMed] [Google Scholar]
  19. Liu T., Soong S. J. Epidemiology of malignant melanoma. Surg Clin North Am. 1996 Dec;76(6):1205–1222. doi: 10.1016/s0039-6109(05)70511-9. [DOI] [PubMed] [Google Scholar]
  20. Lê M. G., Cabanes P. A., Desvignes V., Chanteau M. F., Mlika N., Avril M. F. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control. 1992 May;3(3):199–205. doi: 10.1007/BF00124252. [DOI] [PubMed] [Google Scholar]
  21. MacKie R. M., Freudenberger T., Aitchison T. C. Personal risk-factor chart for cutaneous melanoma. Lancet. 1989 Aug 26;2(8661):487–490. doi: 10.1016/s0140-6736(89)92097-7. [DOI] [PubMed] [Google Scholar]
  22. McCarty K. S., Jr, Wortman J., Stowers S., Lubahn D. B., McCarty K. S., Sr, Seigler H. F. Sex steroid receptor analysis in human melanoma. Cancer. 1980 Sep 15;46(6):1463–1470. doi: 10.1002/1097-0142(19800915)46:6<1463::aid-cncr2820460628>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  23. McClay E. F., Albright K. D., Jones J. A., Christen R. D., Howell S. B. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 1993 Apr 1;53(7):1571–1576. [PubMed] [Google Scholar]
  24. McClay E. F., Mastrangelo M. J., Berd D., Bellet R. E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992 Feb 20;50(4):553–556. doi: 10.1002/ijc.2910500410. [DOI] [PubMed] [Google Scholar]
  25. Mirimanoff R. O., Wagenknecht L., Hunziker N. Long-term complete remission of malignant melanoma with tamoxifen. Lancet. 1981 Jun 20;1(8234):1368–1369. doi: 10.1016/s0140-6736(81)92545-9. [DOI] [PubMed] [Google Scholar]
  26. Nesbit R. A., Woods R. L., Tattersall M. H., Fox R. M., Forbes J. F., MacKay I. R., Goodyear M. Tamoxifen in malignant melanoma. N Engl J Med. 1979 Nov 29;301(22):1241–1242. doi: 10.1056/nejm197911293012218. [DOI] [PubMed] [Google Scholar]
  27. Osterlind A., Tucker M. A., Stone B. J., Jensen O. M. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer. 1988 Sep 15;42(3):319–324. doi: 10.1002/ijc.2910420303. [DOI] [PubMed] [Google Scholar]
  28. Osterlind A., Tucker M. A., Stone B. J., Jensen O. M. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer. 1988 Dec 15;42(6):821–824. doi: 10.1002/ijc.2910420603. [DOI] [PubMed] [Google Scholar]
  29. Palmer J. R., Rosenberg L., Strom B. L., Harlap S., Zauber A. G., Warshauer M. E., Shapiro S. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control. 1992 Nov;3(6):547–554. doi: 10.1007/BF00052752. [DOI] [PubMed] [Google Scholar]
  30. SNELL R. S., BISCHITZ P. G. The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol. 1960 Aug;35:73–82. doi: 10.1038/jid.1960.87. [DOI] [PubMed] [Google Scholar]
  31. Telhaug R., Klepp O., Børmer O. Phase II study of tamoxifen in patients with metastatic malignant melanoma. Cancer Treat Rep. 1982 Jun;66(6):1437–1437. [PubMed] [Google Scholar]
  32. Wagstaff J., Thatcher N., Rankin E., Crowther D. Tamoxifen in the treatment of metastatic malignant melanoma. Cancer Treat Rep. 1982 Sep;66(9):1771–1771. [PubMed] [Google Scholar]
  33. Weinstock M. A., Colditz G. A., Willett W. C., Stampfer M. J., Bronstein B. R., Mihm M. C., Jr, Speizer F. E. Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics. 1989 Aug;84(2):199–204. [PubMed] [Google Scholar]
  34. Westerdahl J., Olsson H., Måsbäck A., Ingvar C., Jonsson N. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer. 1996 May;73(9):1126–1131. doi: 10.1038/bjc.1996.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Zanetti R., Franceschi S., Rosso S., Bidoli E., Colonna S. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol. 1990 Sep;19(3):522–526. doi: 10.1093/ije/19.3.522. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES